South Carolina · J9155

Injection, Degarelix, 1 Mg in South Carolina

South Carolina Medicare Avg
$3.17
0% below national avg
National Medicare Avg
$3.17
All states combined
Billed Charge (SC)
$9.58
What providers submit
Est. Commercial (SC)
$9.49
National avg: $9.03
Est. Cash / Self-Pay (SC)
$5.66
Typical self-pay discount

Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.

108.6K
Services in SC
73
Providers
N/A
Min Payment
N/A
Max Payment

Top Providers in South Carolina

Provider Medicare Services
Pinto, Vijay M.D. $3.18 28.7K
Butler, Charles M.D. $3.17 7.0K
Gangi, Glenn MD $3.23 6.2K
Whatley, Dennis M.D. $3.18 4.3K
Gajewski, Timothy MD $3.19 3.7K
Shore, Neal DR $3.14 3.3K
Jansen, Robert $3.22 2.7K
Prasad, Sandip MD, MPHIL $3.12 2.6K
Putnam, Harvey PA $3.19 2.6K
Reynolds, Eva NP $3.13 2.6K
Young, Richard DR $3.03 2.3K
Roberts, Brian MD $3.00 2.2K
Hawkins, Brittney APRN $3.18 2.0K
Rich, David M.D. $3.14 1.8K

South Carolina Pricing in Context

In South Carolina, CPT code J9155 (Injection, Degarelix, 1 Mg) carries an average Medicare payment of $3.17 — 0% below the national benchmark of $3.17. 73 providers across the state submitted claims for this procedure in 2023, performing 108.6K total services. Individual payments in SC ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in South Carolina is $9.58, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because South Carolina sits below the national Medicare average, commercial rates in the state may also run lower than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Drugs (Administered) procedures, the estimated commercial insurance price in South Carolina lands near $9.49, with self-pay cash prices typically around $5.66. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.

Frequently Asked Questions

How much does Injection, Degarelix, 1 Mg cost in South Carolina?

The average Medicare payment for Injection, Degarelix, 1 Mg in South Carolina is $3.17, which is 0% below the national average of $3.17. Providers in SC typically bill $9.58 for this procedure.

What does Injection, Degarelix, 1 Mg cost with insurance in South Carolina?

With commercial insurance in South Carolina, Injection, Degarelix, 1 Mg costs an estimated $9.49. Without insurance, the estimated cash price is $5.66. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.

How many providers perform Injection, Degarelix, 1 Mg in South Carolina?

73 providers in South Carolina billed Medicare for Injection, Degarelix, 1 Mg in 2023, performing 108.6K total services. Medicare payments ranged from N/A to N/A depending on the provider.

Is Injection, Degarelix, 1 Mg cheaper in South Carolina than the national average?

Yes — Injection, Degarelix, 1 Mg costs 0% below the national average in South Carolina. The state average Medicare payment is $3.17 compared to $3.17 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.

Related

Data sourced from the CMS Medicare Physician and Other Practitioners dataset. See our methodology for details. Retrieved and formatted by PlainProcedure Editorial